Tag - IMGN

Developments

ImmunoGen IMGN632 gets FDA breakthrough therapy designation

The FDA granted ImmunoGen’s (NASDAQ:IMGN) IMGN632 breakthrough therapy designation for the treatment of relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive form of...

October 5, 2020

Markets

Analysts up ImmunoGen PTs on FDA accelerated approval pathway

Analysts for H.C. Wainwright and SVB Leerink raised their price targets for ImmunoGen (NASDAQ:IMGN) after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer (prOC) could support accelerated...

December 17, 2019

Tag - IMGN

ImmunoGen IMGN632 gets FDA breakthrough therapy designation

Analysts up ImmunoGen PTs on FDA accelerated approval pathway

General

More